Table 1.
Patient characteristics by race/ethnicity
| Characteristic | Total N = 2185 |
NHW n = 1666 |
Black/AA (non-Hispanic) n = 155 |
Hispanic (any) n = 288 |
Other minority n = 76 |
P value |
|---|---|---|---|---|---|---|
| Age (y) at diagnosis, median (IQR) | 63 (42-72.5) | 65 (55-73) | 51 (39-62) | 56 (41-65.5) | 63 (42-72.5) | <.0001 |
| Male, (%) | 1237 (56.6%) | 959 (57.6%) | 80 (51.6%) | 160 (55.6%) | 38 (50.0%) | .30 |
| ECOG PS ≥2 (%) | 333 (16.2%) | 269 (17.1%) | 19 (13.1%) | 34 (12.5%) | 11 (16.9%) | .19 |
| Ann Arbor stage, III-IV (%) | 1331 (63.9%) | 1008 (63.4%) | 108 (73.5%) | 171 (62.6%) | 44 (60.3%) | .085 |
| Extranodal sites > 1 (%) | 568 (26.6%) | 414 (25.4%) | 48 (31.8%) | 88 (31.0%) | 18 (24.3%) | .1099 |
| Elevated LDH (%) | 1143 (56.4%) | 849 (54.8%) | 87 (61.7%) | 161 (59.9%) | 46 (66.7%) | .059 |
| IPI | .020 | |||||
| 0-2 | 1353 (62%) | 1020 (61%) | 101 (65%) | 183 (64%) | 49 (64%) | |
| 3-5 | 832 (38%) | 646 (39%) | 54 (35%) | 105 (36%) | 27 (36%) | |
| DTI in days, median (IQR) | 21 (12-33) | 21 (12-32) | 24 (13-39) | 21 (13-33) | 17 (9-33) | .027 |
| B-symptoms (%) | 699 (32.0%) | 508 (30.5%) | 68 (43.9%) | 107 (37.2%) | 16 (21.1%) | .0007 |
| Bone marrow involvement (%) | 276 (15.9%) | 217 (16.5%) | 26 (20.8%) | 26 (10.9%) | 7 (11.7%) | .14 |
| 1L Treatment received | <.0001 | |||||
| R-CHOP | 1402 (64.2%) | 1111 (66.7%) | 86 (55.5%) | 162 (56.3%) | 43 (56.6%) | |
| R-EPOCH | 576 (26.4%) | 385 (23.1%) | 56 (36.1%) | 107 (37.2%) | 28 (36.8%) | |
| Clinical trial | 189 (8.6%) | 159 (9.5%) | 11 (7.1%) | 14 (4.9%) | 5 (6.6%) | |
| Other IC | 18 (0.8%) | 11 (0.7%) | 2 (1.3%) | 5 (1.7%) | 0 (0.0%) |
ECOG PS, Eastern Cooperative Oncology Group performance status; DTI, diagnosis to treatment interval; 1L, first line; LDH, lactate dehydrogenase; IPI, international prognostic index; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R-EPOCH, rituximab, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone.